drugset / Trial / NCT00828802
Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what dose of lenalidomide is safe to use in combination with decitabine when given in people with myelodysplastic syndrome.
Timeline
- Start
- 2009-03
- Primary completion
- 2012-08
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 5 mg | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Subject | Lenalidomide | Other / unclassified | 20 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |